Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Abbisko Cayman FCF Yield % Related Terms
Abbisko Cayman FCF Yield % Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8ZD vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Abbisko Cayman's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (FRA:8ZD) has a FCF Yield % of 1.03 as of Aug. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Abbisko Cayman and its competitors. According to the industry distribution chart, Abbisko Cayman ranks #193 out of 1409 companies in the Biotechnology industry, placing it in the top 13.7%.
Is Abbisko Cayman's FCF Yield % too high?
Abbisko Cayman's current FCF Yield % is 1.03. Based on the distribution chart, Abbisko Cayman ranks #193 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abbisko Cayman has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #193 out of 1409 companies for FCF Yield %. This places Abbisko Cayman in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Abbisko Cayman and its competitors. Abbisko Cayman's current FCF Yield % is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (FRA:8ZD) is currently considered Fairly Valued. The stock's GF Value™ is €1.38, compared to a current price of €1.18 — trading 14.5% below its estimated fair value. The current FCF Yield % is 1.03. Abbisko Cayman's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Abbisko Cayman (FRA:8ZD), the current FCF Yield % is 1.03 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (FRA:8ZD) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of €1.18 is trading 14.5% below its estimated GF Value™ of €1.38.
GuruFocus considers Abbisko Cayman to be Fairly Valued.
Key valuation signals for FRA:8ZD:
FCF Yield %: 1.03
GF Value™: €1.38 vs. price of €1.18 (14.5% below fair value)
No single metric tells the full story. See the FRA:8ZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
55GF Score
Get the complete analysis for FRA:8ZD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8ZD has been successfully added to your 
